Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01463007 · ClinicalTrials.gov registry record · NA

Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer

A NA study of Breast Cancer, sponsored by Jaroslaw Hepel.

Completed
Registry status
NA
Development phase
40
Enrollment target
4
Study locations

NCT01463007: Completed NA study of Breast Cancer, sponsored by Jaroslaw Hepel.

NCT01463007 is a NA study of Breast Cancer that has completed, run by Jaroslaw Hepel. The registered enrollment target is 40 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01463007, a NA study of Breast Cancer, has completed, sponsored by Jaroslaw Hepel.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to evaluate the rate of early and intermediate toxicity related to the AccuBoost System for delivery of APBI in women with resected, early stage breast cancer.

Conditions Studied

Interventions

  • RADIATION Accelerated partial breast irradiation
  • OTHER Extended Follow up

Study Locations (4)

Rhode Island

  • Brown University Oncology Research Group - Providence
  • Lifespan Hospitals - Providence

Florida

  • Center For Cancer Care and Research- Watson Clinic - Lakeland

Washington

  • Tacoma Radiation - Tacoma

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2011-08
Est. Completion 2021-04-06
Phase NA

Sponsor

Jaroslaw Hepel

1 total trials

What the Registry Record Tells You About NCT01463007

The ClinicalTrials.gov registry entry for NCT01463007 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Jaroslaw Hepel, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Accelerated partial breast irradiation is the first listed.

NCT01463007 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Rhode Island, Florida, Washington.

Frequently Asked Questions

What is clinical trial NCT01463007 about?

NCT01463007 is a clinical study titled "Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer". The purpose of this study is to evaluate the rate of early and intermediate toxicity related to the AccuBoost System for delivery of APBI in women with resected, early stage breast cancer.

What is the current status of trial NCT01463007?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2011-08. Estimated completion is 2021-04-06.

What conditions does trial NCT01463007 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT01463007?

The interventions under investigation include: Accelerated partial breast irradiation (RADIATION), Extended Follow up (OTHER).

Who is sponsoring clinical trial NCT01463007?

This trial is sponsored by Jaroslaw Hepel, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01463007 being conducted?

This trial has 4 study locations across Florida, Rhode Island, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.